Paper Details

  1. Home
  2. Paper Details

Review of Ruxolitinib for Treatment of Non-Segmental Vitiligo.

Author: DriscollMarcia S, HwangJacqueline R

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Topical ruxolitinib cream is the first FDA-approved treatment for repigmentation of nonsegmental vitiligo. Two Phase II trials showed significant improvement in Vitiligo Area Scoring Index (VASI) scores with 1.5% concentration applied twice daily. After 52 weeks, 58% of patients showed 50% VASI improvement, 52% showed 75% VASI improvement, and 33% showed 90% VASI improvement. Ruxolitinib is associated with low bioavailability and minimal adverse effects compared to conventional therapies.
Paper Details　
Original Abstract of the Article :
OBJECTIVE: To review the pharmacokinetics, efficacy, and safety of topical ruxolitinib for treatment of nonsegmental vitiligo. DATA SOURCES: Literature published between January 1983 and October 2022 was reviewed from MEDLINE and ClinicalTrials.gov. STUDY SELECTION AND DATA EXTRACTION: Relevant ar...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1177/10600280221143748

データ提供：米国国立医学図書館（NLM）

Vitiligo: A Skin Condition Seeking Solutions in the Desert of Pigmentation

Vitiligo is a skin condition that causes patches of depigmentation, leading to visible white areas on the skin. This research explores the use of topical ruxolitinib, a new medication, for treating nonsegmental vitiligo. They review clinical trial data showing that topical ruxolitinib can effectively repigment the skin, offering a potential new treatment option for this condition. This study highlights the ongoing search for effective treatments for vitiligo, a condition that can significantly impact a person's self-esteem and quality of life.

Ruxolitinib: A New Hope in the Desert of Pigmentation

This research shows that topical ruxolitinib can effectively repigment the skin in patients with nonsegmental vitiligo. It's like discovering a hidden spring in the desert, offering a source of relief for those struggling with depigmentation. This study provides hope for a future where vitiligo can be managed more effectively, improving the lives of those affected by this condition.

Living Well With Vitiligo

This research is a reminder that vitiligo is a treatable condition. It's important to seek professional help if you are experiencing symptoms of vitiligo, as there are effective treatment options available.

Dr.Camel's Conclusion

This research explores the potential of ruxolitinib as a treatment for vitiligo, a condition that can significantly impact a person's self-image. It's a reminder that even in the seemingly barren landscape of skin disorders, there are ongoing efforts to develop new and effective treatments, offering hope for a future where vitiligo can be managed more effectively.

Date :
  1. Date Completed 2023-07-10
  2. Date Revised 2023-07-18
Further Info :

Pubmed ID

36564903

DOI: Digital Object Identifier

10.1177/10600280221143748

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.